MediWound
MDWD
About: MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Employees: 111
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
303% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $441K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
29% more capital invested
Capital invested by funds: $66.6M [Q1] → $86M (+$19.4M) [Q2]
6% more funds holding
Funds holding: 64 [Q1] → 68 (+4) [Q2]
2.97% more ownership
Funds ownership: 38.13% [Q1] → 41.1% (+2.97%) [Q2]
24% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 25
Financial journalist opinion
Based on 3 articles about MDWD published over the past 30 days
